By Fineline Cube 
Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1% year-over-year (YOY) increase, according to its financial results released this week. The company’s Growth Portfolio delivered $6.2 billion in revenue, up 9% YOY, driven primarily by strong performances from Camzyos, Breyanzi, and Reblozyl, while the Legacy Portfolio declined 8% YOY to $5.3 billion amid ongoing generic competition.
Financial Performance Summary
| Metric | Q1 2026 | YOY Change |
|---|---|---|
| Total Revenue | $11.489 billion | +1% |
| Growth Portfolio | $6.2 billion | +9% |
| Legacy Portfolio | $5.3 billion | -8% |
Key Product Performance Highlights
Oncology Franchise
- Opdivo (nivolumab): $2.146 billion (-8% YOY)
- Yervoy (ipilimumab): $651 million (+2% YOY)
- Breyanzi (lisocabtagene maraleucel): $410 million (+53% YOY)
- Reblozyl (luspatercept): $555 million (+15% YOY)
Cardiovascular & Other
- Eliquis (apixaban): $4.137 billion (+13% YOY)
- Camzyos (mavacamten): $314 million (+4% YOY)
The 13% growth in Eliquis sales was partially offset by continued generic erosion affecting other Legacy Portfolio products, resulting in the overall portfolio decline.
Strategic Outlook & Guidance
- Full-Year 2026 Revenue Guidance: $46.0–47.5 billion
- Global Apixaban Sales Growth Expectation: 10%–15%
- Growth Portfolio Momentum: Continued strong uptake of cell therapy (Breyanzi) and cardiovascular innovation (Camzyos)
- Legacy Portfolio Challenges: Ongoing patent expirations and generic competition expected to persist throughout 2026
The company’s strategic pivot toward its Growth Portfolio is yielding positive results, with cell therapy and targeted oncology assets demonstrating robust commercial adoption. Breyanzi’s 53% growth reflects increasing market penetration in large B-cell lymphoma, while Reblozyl continues to expand in myelodysplastic syndromes and beta thalassemia indications.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, product sales, and business strategy. Actual results may differ due to risks including competitive dynamics, regulatory changes, market conditions, and generic competition.-Fineline Info & Tech